These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 27012617)
1. Formulation, characteristics and antiatherogenic bioactivities of CD36-targeted epigallocatechin gallate (EGCG)-loaded nanoparticles. Zhang J; Nie S; Martinez-Zaguilan R; Sennoune SR; Wang S J Nutr Biochem; 2016 Apr; 30():14-23. PubMed ID: 27012617 [TBL] [Abstract][Full Text] [Related]
2. Anti-atherogenic effects of CD36-targeted epigallocatechin gallate-loaded nanoparticles. Zhang J; Nie S; Zu Y; Abbasi M; Cao J; Li C; Wu D; Labib S; Brackee G; Shen CL; Wang S J Control Release; 2019 Jun; 303():263-273. PubMed ID: 30999008 [TBL] [Abstract][Full Text] [Related]
3. Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles. Nie S; Zhang J; Martinez-Zaguilan R; Sennoune S; Hossen MN; Lichtenstein AH; Cao J; Meyerrose GE; Paone R; Soontrapa S; Fan Z; Wang S J Control Release; 2015 Dec; 220(Pt A):61-70. PubMed ID: 26450668 [TBL] [Abstract][Full Text] [Related]
4. Nanoencapsulation enhances epigallocatechin-3-gallate stability and its antiatherogenic bioactivities in macrophages. Zhang J; Nie S; Wang S J Agric Food Chem; 2013 Sep; 61(38):9200-9. PubMed ID: 24020822 [TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin-3-gallate Reduces Scavenger Receptor A Expression and Foam Cell Formation in Human Macrophages. Chen SJ; Kao YH; Jing L; Chuang YP; Wu WL; Liu ST; Huang SM; Lai JH; Ho LJ; Tsai MC; Lin CS J Agric Food Chem; 2017 Apr; 65(15):3141-3150. PubMed ID: 28367625 [TBL] [Abstract][Full Text] [Related]
6. Improving the effectiveness of (-)-epigallocatechin gallate (EGCG) against rabbit atherosclerosis by EGCG-loaded nanoparticles prepared from chitosan and polyaspartic acid. Hong Z; Xu Y; Yin JF; Jin J; Jiang Y; Du Q J Agric Food Chem; 2014 Dec; 62(52):12603-9. PubMed ID: 25483592 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticles target intimal macrophages in atherosclerotic lesions. Dhanasekara CS; Zhang J; Nie S; Li G; Fan Z; Wang S Nanomedicine; 2021 Feb; 32():102346. PubMed ID: 33259961 [TBL] [Abstract][Full Text] [Related]
8. The Development of Hyaluronan/Fucoidan-Based Nanoparticles as Macrophages Targeting an Epigallocatechin-3-Gallate Delivery System. Ho CH; Chu PY; Peng SL; Huang SC; Lin YH Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32878305 [TBL] [Abstract][Full Text] [Related]
9. Dietary compound quercitrin dampens VEGF induction and PPARgamma activation in oxidized LDL-exposed murine macrophages: association with scavenger receptor CD36. Choi JS; Bae JY; Kim DS; Li J; Kim JL; Lee YJ; Kang YH J Agric Food Chem; 2010 Jan; 58(2):1333-41. PubMed ID: 19928818 [TBL] [Abstract][Full Text] [Related]
10. Green tea epigallocatechin-3-gallate attenuates Porphyromonas gingivalis-induced atherosclerosis. Cai Y; Kurita-Ochiai T; Hashizume T; Yamamoto M Pathog Dis; 2013 Feb; 67(1):76-83. PubMed ID: 23620122 [TBL] [Abstract][Full Text] [Related]
11. Intermedin inhibits macrophage foam-cell formation via tristetraprolin-mediated decay of CD36 mRNA. Dai XY; Cai Y; Sun W; Ding Y; Wang W; Kong W; Tang C; Zhu Y; Xu MJ; Wang X Cardiovasc Res; 2014 Feb; 101(2):297-305. PubMed ID: 24253523 [TBL] [Abstract][Full Text] [Related]
12. Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation. Frias I; Neves AR; Pinheiro M; Reis S Drug Des Devel Ther; 2016; 10():3519-3528. PubMed ID: 27826184 [TBL] [Abstract][Full Text] [Related]
13. Rapamycin-Loaded Polymeric Nanoparticles as an Advanced Formulation for Macrophage Targeting in Atherosclerosis. Craparo EF; Cabibbo M; Conigliaro A; Barreca MM; Musumeci T; Giammona G; Cavallaro G Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33916918 [TBL] [Abstract][Full Text] [Related]
14. Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1-PPARγ-CD36 pathway. Yang X; Yin M; Yu L; Lu M; Wang H; Tang F; Zhang Y Can J Physiol Pharmacol; 2016 Dec; 94(12):1336-1343. PubMed ID: 27733051 [TBL] [Abstract][Full Text] [Related]
15. (-)-Epigallocatechin gallate (EGCG)-nanoethosomes as a transdermal delivery system for docetaxel to treat implanted human melanoma cell tumors in mice. Liao B; Ying H; Yu C; Fan Z; Zhang W; Shi J; Ying H; Ravichandran N; Xu Y; Yin J; Jiang Y; Du Q Int J Pharm; 2016 Oct; 512(1):22-31. PubMed ID: 27544847 [TBL] [Abstract][Full Text] [Related]
16. The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate. Ray L; Kumar P; Gupta KC Biomaterials; 2013 Apr; 34(12):3064-76. PubMed ID: 23357370 [TBL] [Abstract][Full Text] [Related]
19. Tumor-Homing Cell-Penetrating Peptide Linked to Colloidal Mesoporous Silica Encapsulated (-)-Epigallocatechin-3-gallate as Drug Delivery System for Breast Cancer Therapy in Vivo. Ding J; Yao J; Xue J; Li R; Bao B; Jiang L; Zhu JJ; He Z ACS Appl Mater Interfaces; 2015 Aug; 7(32):18145-55. PubMed ID: 26225796 [TBL] [Abstract][Full Text] [Related]
20. pH and temperature stability of (-)-epigallocatechin-3-gallate-β-cyclodextrin inclusion complex-loaded chitosan nanoparticles. Liu F; Majeed H; Antoniou J; Li Y; Ma Y; Yokoyama W; Ma J; Zhong F Carbohydr Polym; 2016 Sep; 149():340-7. PubMed ID: 27261758 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]